Tirzepatide side effects week 2: what the data actually says

What did @conciergenurse actually say?

This is a patient check-in video. Rosie, a client of @conciergenurse, describes her second week on tirzepatide. She says week two was "definitely better than the first week symptom-wise" and credits eating enough protein and staying on top of nutrition for the improvement. She mentions "sick and headache" that kept her in bed on the first day after injection, which resolved once she ate and drank. The nurse prompts her about protein intake, suggesting "about 60" grams as a target. Rosie says she eats "all protein all day" with some fiber. She also notes symptoms tended to worsen "at the end of the week" in week one but did not repeat that pattern in week two.

There are no dramatic weight-loss claims here, no dosing recommendations beyond naming the 5mg starting tier, and no promises of outcomes. This is a relatively grounded patient testimonial framed as an informal side-effect update.

Does the science back this up?

Mostly, yes. The side-effect pattern Rosie describes, nausea, fatigue, and headache concentrated in the first 24-72 hours after injection, is well-documented in tirzepatide trial data. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) reported nausea in roughly 30% of participants, predominantly in early weeks and peaking shortly after dose escalation. The observation that symptoms improved week over week is consistent with clinical experience and the pharmacokinetic profile of tirzepatide, which has a roughly 5-day half-life.

The protein advice is more nuanced. A 60-gram daily protein floor is on the low end for someone using a GLP-1/GIP receptor agonist, where appetite suppression can accelerate lean mass loss. Padhi et al. (2020, Clinical Nutrition ESPEN) and work by Aragon and Schoenfeld (2013, Journal of the International Society of Sports Nutrition) suggest higher targets, 1.2 to 1.6 grams per kilogram of body weight, are preferable when in a caloric deficit. The 60g figure is not wrong, but it may be insufficient depending on Rosie's body weight.

What did they get right, and what deserves scrutiny?

Credit where it is due: framing side effects as variable week to week is accurate and genuinely useful for patients who panic after a rough first injection. The encouragement to eat and stay hydrated to manage symptoms is consistent with clinical guidance. Tirzepatide's gastrointestinal side effects are often worsened by skipping meals or dehydration, so this is practical, evidence-aligned advice.

The 60-gram protein target deserves more scrutiny. It is not dangerous, but for a patient who is eating significantly less due to appetite suppression, 60 grams may not protect lean muscle mass. No body weight or activity level is given for Rosie, so we cannot say it is wrong for her specifically, but presenting it as a general benchmark without context is incomplete guidance.

The nurse also normalizes the first-day-after-injection symptom window without explicitly naming it as the post-injection period. Patients who do not understand that timing may misattribute symptoms to food, stress, or illness instead of the medication itself.

What should you actually know?

Tirzepatide side effects, particularly nausea, headache, and fatigue, are common in the first several weeks and tend to improve with time. This is not unique to 5mg; it typically recurs to some degree at each dose escalation. The SURMOUNT program data consistently shows GI adverse events are highest early and taper off, which tracks with Rosie's experience.

Protein intake during GLP-1 therapy matters more than most patient-facing content acknowledges. A 2023 analysis by Wilding et al. published in Diabetes, Obesity and Metabolism noted that weight lost on GLP-1 agonists includes a meaningful proportion of lean mass, a concern that adequate protein and resistance exercise can help mitigate. Sixty grams is a floor, not necessarily a target, and patients should discuss individualized protein goals with their provider.

Finally, this video is from a specific Dallas-based telehealth practice. The advice here is not universally prescriptive. Individual side-effect profiles vary, and what worked for Rosie in week two may not reflect your experience.